30 completed, 8 recruiting, 4 terminated, 4 unknown. 51 Phase 2, 8 Phase 1, 7 Phase 3.
Follow Personality Disorders: new trials by email Literature Review of Personality Disorders trials Research Report on Personality Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder IV Ketamine (0.5 mg/kg) Infusion - Two Doses Administered 24 Hours Apart for Severe Borderline Personality Disorder - Infusion of Ketamine in Severe Borderline Personality Disorder, Borderline Personality Disorder (BPD) | Phase 2 | Not yet recruiting | University Hospital, Toulouse | 38 | 2027-01-01 | 2026-11-04 |
| SONATA Dose Duration LIFU for OCD ATTN201 - Low Intensity Focused Ultrasound - Obsessive - Compulsive Disorder | Phase 2 | Recruiting | University of Pennsylvania | 20 | 2026-09-15 | 2026-10-21 |
| Psilocybin for Treatment of OCD-2 Low Dose Psilocybin, High Dose Psilocybin - Obsessive - Compulsive Disorder | Phase 1 / Phase 2 | Not yet recruiting | Francisco A Moreno | 20 | 2026-09-08 | 2026-05-12 |
| Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT) Ketamine Hydrochloride, Midazolam Hydrochloride, Dialectical Behavioral Therapy (DBT) - Borderline Personality Disorder (BPD), Treatment-Resistant Major Depressive Disorder | Phase 2 | Recruiting | Joshua Rosenblat | 120 | 2026-07-16 | 2026-07-29 |
| A Pilot Trial of One-Day Accelerated TMS and D-cycloserine in Suicidal Patients With Borderline Personality Disorder TMS, D-Cycloserine (DCS) - Borderline Personality Disorder (BPD) | Phase 1 / Phase 2 | Recruiting | Mclean Hospital | 20 | 2026-06-10 | 2026-08-05 |
| MDMA in Borderline Personality Disorder MDMA - Borderline Personality Disorder | Phase 2 | Recruiting | Yale University | 10 | 2025-09-05 | 2026-10-22 |
| Testing Interventions for Borderline Personality Disorder. Sage, Supportive Individual Psychotherapy - Borderline Personality Disorder | Phase 2 | Recruiting | York University | 304 | 2025-09-01 | 2026-04-01 |
| Brain Signal Training to Enhance Affect Down-regulation Amygdala neurofeedback, Sham neurofeedback - Borderline Personality Disorder | Phase 1 / Phase 2 | Recruiting | Central Institute of Mental Health, Mannheim | 164 | 2025-04-23 | 2026-08-17 |
| Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder mindfulness-based Neurofeedback, control Neurofeedback - Borderline Personality Disorder | Phase 2 | Active not recruiting | Yale University | 46 | 2025-03-13 | 2026-10-19 |
| Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder Psilocybin - Borderline Personality Disorder, Major Depressive Disorder | Phase 2 | Completed | University of Chicago | 10 | 2023-11-01 | 2026-10-29 |
| Caplyta in Borderline Personality Disorder Caplyta, Placebo - Borderline Personality Disorder | Phase 2 | Completed | University of Chicago | 60 | 2023-05-10 | 2026-07-29 |
| Accelerated TMS in Psychosis repetitive Transcranial Magnetic Stimulation (rTMS) - Schizophrenia, Schizoaffective Disorder | Phase 1 / Phase 2 | Suspended | Beth Israel Deaconess Medical Center | 20 | 2022-11-29 | 2026-04-22 |
| Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer NMDAE, Placebo Cap - Prodromal Schizophrenia | Phase 2 | Recruiting | China Medical University Hospital | 48 | 2021-11-01 | 2026-03-24 |
| Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population vafidemstat, Placebo - Borderline Personality Disorder | Phase 2 | Completed | Oryzon Genomics S.A. | 211 | 2021-03-26 | 2026-05-05 |
| A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder BI 1358894, Placebo - Borderline Personality Disorder | Phase 2 | Completed | Boehringer Ingelheim | 390 | 2020-11-13 | 2024-01-30 |
| Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD) Brexpiprazole - Borderline Personality Disorder | Phase 2 / Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 201 | 2020-01-13 | 2024-10-03 |
| A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder Brexpiprazole, Placebo - Borderline Personality Disorder | Phase 2 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 332 | 2019-10-17 | 2024-07-18 |
| Brexpiprazole in Borderline Personality Disorder Rexulti, Placebo - Borderline Personality Disorder | Phase 2 | Completed | University of Chicago | 80 | 2018-11-26 | 2022-03-18 |
| Ketamine in Borderline Personality Disorder Ketamine, Midazolam - Borderline Personality Disorder | Phase 2 | Terminated | Yale University | 22 | 2018-02-15 | 2023-06-26 |
| Emotional Regulation and Impulsivity Among Adolescents with Borderline Personality Disorder Clinical assessment, Stress elicitation experiment, Structural and Functional MRI - Borderline Personality Disorder, Adolescent Development | Phase 2 | Active not recruiting | Institut National de la Santé Et de la Recherche Médicale, France | 66 | 2017-10-04 | 2025-03-13 |
Showing 20 of 51. Sign in to see all of them.
Borderline Personality Disorder (29) · Antisocial Personality Disorder (8) · Anxiety Disorders (6) · Schizotypal Personality Disorder (6) · Compulsive Personality Disorder (4) · Depressive Disorder, Major (4) · Self-Injurious Behavior (4) · Substance-Related Disorders (4) · Cognitive Dysfunction (3) · Depression (3) · Mental Disorders (3) · Mood Disorders (3) · Obsessive-Compulsive Disorder (3) · Suicide (3)
Mental Disorders (48) · Behavior (15) · Behavioral Symptoms (12) · Chemically-Induced Disorders (5) · Depressive Disorder (4) · Mood Disorders (4) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Nervous System Diseases (3) · Neurocognitive Disorders (3) · Neurologic Manifestations (3) · Self-Injurious Behavior (3) · Social Behavior (3) · Aberrant Motor Behavior in Dementia (2)
Ketamine (3) · Therapeutics (3) · brexpiprazole (3) · Docosahexaenoic Acids (2) · Midazolam (2) · Psilocybin (2) · dihydrexidine (2) · Acetaminophen (1) · Acetylcysteine (1) · Acupuncture Therapy (1) · Ascorbic Acid (1) · Botulinum Toxins, Type A (1) · Citalopram (1) · Cognitive Behavioral Therapy (1) · Cycloserine (1)
Yale University (5) · University of Chicago (4) · Central Institute of Mental Health, Mannheim (2) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (2) · Otsuka Pharmaceutical Development & Commercialization, Inc. (2) · University of Oslo (2) · University of Washington (2) · Antonia New (1) · AstraZeneca (1) · Beth Israel Deaconess Medical Center (1) · Boehringer Ingelheim (1) · China Medical University Hospital (1) · Columbia Northwest Pharmaceuticals (1) · Columbia University (1) · Dr. Annis Fung (1)
United States (30) · Germany (5) · Spain (4) · France (3) · Australia (2) · Bulgaria (2) · Canada (2) · Netherlands (2) · Norway (2) · Sweden (2) · United Kingdom (2) · Argentina (1) · Belgium (1) · China (1) · Czechia (1)
Jon E Grant, MD, JD, MPH (2) · Adrian Raine (1) · Annette M. van Schagen, MA (1) · Annis Fung, Ph.D. (1) · Antonia S. New, MD (1) · Arifulla Khan, MD (1) · Baldwin M Way, Ph.D. (1) · Carolyn Westhoff, MD (1) · Christian Paret-Voigt, Dr. (1) · Christian Schmahl, MD (1) · Christopher J Pittenger, MD, Ph.D. (1) · Christopher J Pittenger, MD,PhD (1) · Cynthia T McEvoy, MD,MCR (1) · Cyril Dalais, MSc (1)
PMID 36375174, PMID 32368793, PMID 33884617, PMID 39558901, PMID 17012684, PMID 18251623, PMID 19254438, PMID 19845088, PMID 20048226, PMID 20732631, PMID 20869813, PMID 21859184, PMID 22373759, PMID 22503959, PMID 23444147, PMID 24029539, PMID 24376516, PMID 24562087, PMID 24677205, PMID 25146492, PMID 25404145, PMID 25806661, PMID 26062135, PMID 26214725, PMID 26455674, PMID 26727409, PMID 27600314, PMID 29549516, PMID 30522343, PMID 30865304, PMID 31651367, PMID 32216138, PMID 32252696, PMID 32404003, PMID 34538263, PMID 35102782, PMID 38413986, PMID 39832346, PMID 40629288, PMID 41044653, PMID 41332880, PMID 41860884
2019 (1), K23DA027720 (1), KL2RR025754-04 (1), R01HL105447 (1), R01MH034486 (1), R01MH097799 (1), R34MH082143 (1), R34MH083115 (1), R61MH135009 (1)